Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data
Covered in this story
Call it yourself
No calls on $CADL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Candel Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.